Makes rifapentine-based treatment available at an affordable price to support TB prevention in low-and middle-income countries

Pharma Major Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Rifampin Capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (FDA).